Patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment are at high risk for recurrence. Take this quiz to test your knowledge of the results of a recent study presented at the ESMO Congress 2025 that assessed recurrence rates of invasive disease after treatment with trastuzumab deruxtecan compared with ado-trastuzumab emtansine.
